- Trials with a EudraCT protocol (297)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
297 result(s) found for: Relapsing-remitting.
Displaying page 6 of 15.
EudraCT Number: 2009-016824-29 | Sponsor Protocol Number: 1232009 | Start Date*: 2010-04-06 | |||||||||||
Sponsor Name:Dansk Multipel Sclerose Center | |||||||||||||
Full Title: REsPons på interferon-Alfa hos InterfeRon-β-neutraliserende antistof-positive patienter med multipel sklerose | |||||||||||||
Medical condition: Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013695-46 | Sponsor Protocol Number: 701068-524 | Start Date*: 2009-10-22 | |||||||||||
Sponsor Name:MERCK SERONO s.a.s | |||||||||||||
Full Title: ETUDE MULTICENTRIQUE, RANDOMISEE EN DOUBLE AVEUGLE VERSUS PLACEBO EVALUANT L’EFFICACITE D’UN TRAITEMENT ADDITIONNEL PAR CHOLECALCIFEROL (VITAMINE D3) CHEZ DES PATIENTS ATTEINTS DE SCLEROSE EN PLAQU... | |||||||||||||
Medical condition: Sclérose en plaques récurrente (SEP-R) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011523-31 | Sponsor Protocol Number: 09/H0720/64 | Start Date*: 2009-06-23 | |||||||||||||||||||||
Sponsor Name:R & D, Cambridge University Hospitals | |||||||||||||||||||||||
Full Title: A study of the immune response to vaccination in MS patients treated with alemtuzumab | |||||||||||||||||||||||
Medical condition: The vaccinations are being used to investigate immunological memory following treatment of multiple sclerosis with the lympho-depleting humanised monoclonal antibody alemtuzumab. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-004807-10 | Sponsor Protocol Number: inims-004 | Start Date*: 2013-07-17 | ||||||||||||||||||||||||||
Sponsor Name:University Medical Center Hamburg Eppendorf | ||||||||||||||||||||||||||||
Full Title: Relapse Escalation treatment trial in Optic Neuritis (RESCON): Multi-centre RCT to study the efficacy of plasma exchange (PE) as an escalation treatment strategy in steroid-unresponsive Optic Neuri... | ||||||||||||||||||||||||||||
Medical condition: MS patients who suffer from severe Optic Neuritis without satisfying improvement after treatment with steroids (3-5 days with 1 g daily at least 7 days prior to randomization) and with persisting v... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-005021-11 | Sponsor Protocol Number: 28851 | Start Date*: 2009-10-14 | |||||||||||
Sponsor Name:Merck Serono SA - Geneva, An affiliate of Merck KGaA, Darmstadt, Germany | |||||||||||||
Full Title: An open-label, multicenter phase II extension of study 28063 (ATAMS) to obtain long-term follow-up data in patients with relapsing multiple sclerosis treated with atacicept for up to 5 years (ATAMS... | |||||||||||||
Medical condition: Relapsing multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) SE (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-018084-27 | Sponsor Protocol Number: MS-GA-301 | Start Date*: 2010-03-30 | |||||||||||
Sponsor Name:Teva Pharmaceutical Industries, Ltd. | |||||||||||||
Full Title: A multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of Glatiramer... | |||||||||||||
Medical condition: Relapsing-remitting Multiple Sclerosis (RR MS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) EE (Completed) CZ (Completed) LT (Completed) BG (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000709-10 | Sponsor Protocol Number: UKM12_0026 | Start Date*: 2014-12-19 | |||||||||||
Sponsor Name:Universitätsklinikum Münster | |||||||||||||
Full Title: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential | |||||||||||||
Medical condition: relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005624-98 | Sponsor Protocol Number: 109MS309 | Start Date*: 2015-09-09 | ||||||||||||||||
Sponsor Name:Biogen Idec Research Limited | ||||||||||||||||||
Full Title: A Randomized, Placebo-Controlled, Parallel-Group Study in Pediatric Subjects Ages 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 for the Treatment of Relapsing-Remitting Forms o... | ||||||||||||||||||
Medical condition: Relapsing-Remitting Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Prematurely Ended) EE (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004819-12 | Sponsor Protocol Number: FullResponders | Start Date*: 2018-01-10 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: Discontinuation of first-line disease modifying treatment (DMT) in long-term full responders MS patients: a multicentre randomized clinical trial. | |||||||||||||
Medical condition: Relapsing-Remitting multiple sclerosis (RR-MS), | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023023-19 | Sponsor Protocol Number: CFTY720DIT01 | Start Date*: 2010-12-28 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: A 18-month, open-label, rater-blinded, randomized, multi-center, active-controlled, parallel-group pilot study to assess efficacy and safety of fingolimod (Gilenya) in comparison to interferon beta... | |||||||||||||
Medical condition: relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000499-25 | Sponsor Protocol Number: 28733 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Merck Serono International S.A. | |||||||||||||
Full Title: International, multicenter, single-arm, open-label, 12-week phase IIIb study to evaluate RebiSmartTM suitability for self-injection of Rebif New Formulation (RNF) in multidose cartridges in patien... | |||||||||||||
Medical condition: Relapsing forms of Multiple Sclerosis (RMS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008719-25 | Sponsor Protocol Number: CBAF312A2201 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A phase II, double-blind, randomized, multi-center, adaptive dose-ranging, placebo-controlled, parallel-group study evaluating safety, tolerability and efficacy on MRI lesion parameters and determi... | |||||||||||||
Medical condition: Relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FI (Completed) ES (Completed) IT (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024000-10 | Sponsor Protocol Number: 101MS206 | Start Date*: 2011-06-28 | |||||||||||
Sponsor Name:Biogen Idec Limited | |||||||||||||
Full Title: A Randomized, Blinded, Parallel-Group, Phase 2 Study Exploring the Safety, Tolerability, and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing Multiple Sclerosis | |||||||||||||
Medical condition: Relapsing-Remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000801-28 | Sponsor Protocol Number: MSB-IG-H-2101 | Start Date*: 2023-07-24 | |||||||||||
Sponsor Name:Cellerys AG | |||||||||||||
Full Title: Multicenter, Phase Ib/IIa Study on the Safety and Efficacy of Autologous Peptide-coupled Red Blood Cells in Patients with Relapsing Remitting Multiple Sclerosis | |||||||||||||
Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004736-79 | Sponsor Protocol Number: 1102-CT02 | Start Date*: 2007-03-06 |
Sponsor Name:Antisense Therapeutics Ltd. | ||
Full Title: A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL 1102 (VLA-4 antisense oligonucleotide) by subcutaneous inje... | ||
Medical condition: To evaluate the efficacy of a selected treatment regimen of ATL 1102 in patients with Relapsing Remitting MS (RRMS) inflammatory lesions using MRI with gadolinium administration compared to placebo. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: CZ (Completed) SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-001692-39 | Sponsor Protocol Number: CFTY720DDE06 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Novartis Pharma GmbH | ||||||||||||||||||
Full Title: A 21-week, multicenter, open label study to evaluate the safety and tolerability profile of the combination of a SSRI or SNRI antidepressive therapy with oral fingolimod in the treatment of RRMS pa... | ||||||||||||||||||
Medical condition: Multiple Sclerosis Depression | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-001486-17 | Sponsor Protocol Number: 109MS407 | Start Date*: 2014-05-06 | ||||||||||||||||
Sponsor Name:Biogen Idec Research Limited | ||||||||||||||||||
Full Title: A Multicenter, Open-Label, Single-Arm Study to Evaluate Gastrointestinal Tolerability in Subjects with Relapsing-Remitting Multiple Sclerosis Receiving Dimethyl Fumarate (TOLERATE) | ||||||||||||||||||
Medical condition: Relapsing-Remitting Multiple Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-003577-63 | Sponsor Protocol Number: DYNAMICS_Study | Start Date*: 2022-04-06 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: Effects of ozanimod on myelin dynamics and neurodegeneration in patients with relapsing-remitting multiple sclerosis: correlation with disease activity, cognition, fatigue, depression and quality o... | |||||||||||||
Medical condition: Multiple sclerosis patients in relapse and remission form | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003282-29 | Sponsor Protocol Number: 109MS311 | Start Date*: 2016-06-17 | ||||||||||||||||
Sponsor Name:Biogen Idec Research Limited | ||||||||||||||||||
Full Title: A Multicenter Extension Study to Determine the Long-Term Safety and Efficacy of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis | ||||||||||||||||||
Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) BE (Completed) CZ (Completed) LV (Completed) BG (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-004903-39 | Sponsor Protocol Number: WCNNMBJR001 | Start Date*: 2005-07-26 |
Sponsor Name:The Walton Centre for Neurology and Neurosurgery | ||
Full Title: A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs. Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis. | ||
Medical condition: Early, active relapsing remitting Multiple Sclerosis (RRMS) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
